Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA7 | P43166 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25260946 | 0.87 | TSHR (0.47) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL6858915 | 0.83 | TSHR (0.47) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL17930513 | 0.82 | TSHR (0.46) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL20772841 | 0.81 | CCR6 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1819905 | 0.81 | TSHR (0.48) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL16618315 | 0.81 | TSHR (0.50) | PKMCA12CA1CA2CA7 | |
| SCHEMBL15714032 | 0.81 | ALDH1A1 (0.50) | MAPTPKMCA12CA1CA2 | |
| SCHEMBL22208578 | 0.80 | CA12 (0.54) | MAPTPKMCA12CA1CA2 | |
| SCHEMBL21154860 | 0.79 | TSHR (0.51) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL364335 | 0.79 | TSHR (0.53) | MAPTCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | MAPT 3937/4885PKM 4125/4885CA12 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.